The Japanese Journal of Pediatric Hematology / Oncology
Online ISSN : 2189-5384
Print ISSN : 2187-011X
ISSN-L : 2187-011X
Case Report
Rituximab for treatment of systemic autoimmunity in Wiskott-Aldrich syndrome
Tomohiro NakanoHidetaka NiizumaSaori KatayamaYuko WatanabeMasahiro IrieTakeshi RikiishiYoji SasaharaShigeo Kure
Author information
JOURNAL FREE ACCESS

2019 Volume 56 Issue 2 Pages 221-224

Details
Abstract

Systemic autoimmunity may develop in association with severe Wiskott-Aldrich syndrome (WAS). Here, we present a patient with WAS complicated by steroid-resistant systemic autoimmunity, which was successfully treated with rituximab. A Japanese boy suffered from recurrent infections and eczema, and was genetically diagnosed as having WAS at one month of age. When the patient was 11 months old, he started to develop systemic autoimmune symptoms including dermatitis, vasculitis and arthritis. Rituximab was markedly effective for these symptoms, whereas prednisolone and cyclosporine A were not. After remission of his autoimmunity, he underwent allogeneic umbilical cord blood transplantation as the curative therapy for WAS. As growing attention has been paid recently to humoral immunity in association with the autoimmunity of WAS, rituximab might be one of the key drugs for treating such autoimmunity.

Content from these authors
© 2019 The Japanese Society of Pediatric Hematology / Oncology
Previous article Next article
feedback
Top